We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+19.03%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$4.08B
AUM Growth
+$976M
Cap. Flow
+$264M
Cap. Flow %
6.47%
Top 10 Hldgs %
75.07%
Holding
69
New
11
Increased
11
Reduced
6
Closed
16
Avg Time Held Equity + Options
6 quarters
Top 10 Avg Time Held Equity + Options
8.5 quarters
Top 20 Avg Time Held Equity + Options
7.1 quarters
Avg Time Held Equity only
6.3 quarters
Top 10 Avg Time Held Equity only
8.5 quarters
Top 20 Avg Time Held Equity only
7.1 quarters

Top Buys

Rank Stock Value
1
BPMC icon
Blueprint Medicines
BPMC
+$97.8M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$85.3M
3
LKFT icon
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$61.7M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$49.6M
5
RVMD icon
Revolution Medicines
RVMD
+$45.3M

Top Sells

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$45.3M
2
KYMR icon
Kymera Therapeutics
KYMR
+$23.6M
3
ACET icon
Adicet Bio
ACET
+$20.5M
4
DYN icon
Dyne Therapeutics
DYN
+$18M
5
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 92.91%
2 Miscellaneous 7.09%
3 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PRTA icon
1
Prothena Corp
PRTA
$434M
$791M 19.38%
11,584,280
– –
2018 Q4
18 quarters
APLS icon
2
DELISTED
Apellis Pharmaceuticals
APLS
$497M 12.17%
5,451,647
– –
2021 Q4
6 quarters
SRPT icon
3
Sarepta Therapeutics
SRPT
$1.76B
$419M 10.27%
3,660,798
+661,345
+22% +$85.3M
2022 Q1
5 quarters
JNJ icon
4
CALL
Johnson & Johnson
JNJ
$608B
$281M 6.89%
+1,700,000
New +$274M
2023 Q2
0 quarters
LKFT icon
5
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
$234M 5.73%
5,756,268
+1,511,623
+36% +$61.7M
2021 Q3
7 quarters
MORF icon
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$221M 5.4%
3,846,964
-2
-0% -$104
2019 Q2
16 quarters
RVMD icon
7
Revolution Medicines
RVMD
$41.9B
$193M 4.72%
7,198,700
+1,846,517
+35% +$45.3M
2022 Q1
5 quarters
ANAB icon
8
AnaptysBio
ANAB
$1.39B
$153M 3.75%
7,521,024
– –
2019 Q4
14 quarters
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$3.28B
$143M 3.52%
5,991,479
– –
2021 Q4
6 quarters
XNCR icon
10
Xencor
XNCR
$1.75B
$132M 3.23%
5,282,516
– –
2018 Q4
18 quarters
ZYME icon
11
Zymeworks
ZYME
$1.78B
$116M 2.84%
13,437,473
+3,350,000
+33% +$30M
2022 Q4
2 quarters
BPMC icon
12
DELISTED
Blueprint Medicines
BPMC
$114M 2.78%
+1,798,300
New +$97.8M
2023 Q2
0 quarters
ARVN icon
13
Arvinas
ARVN
$445M
$99.7M 2.44%
4,017,788
+300,000
+8% +$7.72M
2021 Q4
6 quarters
SWTX icon
14
DELISTED
SpringWorks Therapeutics
SWTX
$90.7M 2.22%
3,460,208
– –
2022 Q3
3 quarters
KURA icon
15
Kura Oncology
KURA
$861M
$61.4M 1.51%
5,806,871
-831,500
-13% -$9.83M
2015 Q4
30 quarters
RLAY icon
16
Relay Therapeutics
RLAY
$3.71B
$52.3M 1.28%
4,163,824
– –
2020 Q3
11 quarters
JAZZ icon
17
Jazz Pharmaceuticals
JAZZ
$14B
$45.7M 1.12%
+368,411
New +$49.6M
2023 Q2
0 quarters
VYGR icon
18
Voyager Therapeutics
VYGR
$129M
$44.1M 1.08%
3,851,507
– –
2021 Q3
7 quarters
CNTA
19
DELISTED
Centessa Pharmaceuticals
CNTA
$34.8M 0.85%
5,618,779
– –
2021 Q2
8 quarters
EWTX icon
20
Edgewise Therapeutics
EWTX
$4.05B
$27.1M 0.66%
3,493,194
– –
2021 Q1
9 quarters
ORIC icon
21
Oric Pharmaceuticals
ORIC
$1.19B
$26.5M 0.65%
3,418,068
– –
2020 Q2
12 quarters
AVIR icon
22
Atea Pharmaceuticals
AVIR
$375M
$26.2M 0.64%
6,995,861
+811,000
+13% +$3.04M
2021 Q4
6 quarters
NUVB icon
23
Nuvation Bio
NUVB
$1.67B
$25M 0.61%
13,896,543
– –
2021 Q1
9 quarters
ALEC icon
24
Alector
ALEC
$210M
$24.4M 0.6%
4,056,548
– –
2021 Q1
9 quarters
CRNX icon
25
DELISTED
Crinetics Pharmaceuticals
CRNX
$24M 0.59%
1,330,263
– –
2021 Q4
6 quarters
1
2 3

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q2 2023 Portfolio in Review

As of Q2 2023, EcoR1 Capital held 69 positions worth $4.08B, up 31% from $3.11B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

EcoR1 Capital deployed $264M of net new capital in Q2 2023, opening 11 new positions and adding to 11 existing holdings. Its largest new stake was Blueprint Medicines: 1,798,300 shares worth $114M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 100% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Janux Therapeutics, an estimated $45.3M trimmed.

  • EcoR1 Capital's largest Q2 2023 buy was Blueprint Medicines: 1,798,300 shares worth $114M.
  • EcoR1 Capital added most to Sarepta Therapeutics in Q2 2023, an estimated $85.3M increase.
  • EcoR1 Capital's biggest Q2 2023 reduction was Janux Therapeutics, cutting an estimated $45.3M.
  • EcoR1 Capital fully exited Kymera Therapeutics in Q2 2023, selling an estimated $23.6M.
  • EcoR1 Capital's ten largest holdings make up 75% of its $4.08B portfolio in Q2 2023.
  • EcoR1 Capital opened 11 new positions and closed 16 in Q2 2023.
  • EcoR1 Capital's portfolio value rose 31% quarter-over-quarter to $4.08B.

Based on EcoR1 Capital's 13F filing for Q2 2023, filed 14 Aug 2023.